Citius pharmaceuticals completes enrollment in phase 2b study of halo-lido for the prescription treatment of hemorrhoids

Topline results anticipated by the end of q2 2023 cranford, n.j. , april 3, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr) today announced that the last patient has been enrolled in the company's phase 2b clinical study of halo-lido (citi-002), a topical formulation for the relief of hemorrhoids.
CTXR Ratings Summary
CTXR Quant Ranking